DelveInsight’s “Refractory Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Refractory Metastatic Melanoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Refractory Metastatic Melanoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Refractory Metastatic Melanoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Refractory Metastatic Melanoma: An Overview
Refractory metastatic melanoma refers to melanoma that has spread (metastasized) to other parts of the body and has not responded to previous treatments. Melanoma is a type of skin cancer that arises from the pigment-producing cells (melanocytes) in the skin. When melanoma metastasizes, it can spread to lymph nodes, organs, and other tissues.
Refractory metastatic melanoma manifests in various ways. It may lead to skin changes like irregular moles or discomfort in affected areas. Swollen lymph nodes, fatigue, and appetite loss can occur. Respiratory issues may arise if the cancer spreads to the lungs, while neurological symptoms may signal brain involvement. Digestive problems may emerge if metastases affect the gastrointestinal tract, and bone pain could indicate skeletal involvement. Liver dysfunction may also manifest.
Refractory metastatic melanoma arises from a combination of genetic predisposition and environmental factors like intense UV radiation exposure. Genetic mutations in genes like BRAF and NRAS can heighten susceptibility. Previous melanoma, weakened immune systems, and family history further elevate risks. Fair-skinned individuals, older adults, and those in high UV regions are more prone. While these factors contribute, they do not guarantee melanoma. For those with refractory metastatic cases, underlying causes of treatment resistance can vary, involving genetic mutations, microenvironmental changes, and other factors.
Refractory Metastatic Melanoma Market Key Facts
As per the National Cancer Institute, in 2020, an estimated 6,850 persons died from melanoma in the United States. For melanoma of the skin, death rates are higher among the middle-aged and elderly. More than 65% of the deaths due to melanoma are between the age group of 55 to 85 years.
According to ASCO, in 2023, an estimated 97,610 adults (58,120 men and 39,490 women) in the United States will be diagnosed with invasive melanoma of the skin.
According to the SEER estimates, 106,110 new cases of melanoma were observed in 2021. More than half of the new cases occurred in patients with 60+ years of age.
According to the American Cancer Society, melanoma is more prominent in males than females.
From 2014 to 2018, the incidence rate of melanoma that had spread to distant parts of the body was 0.9 per 100,000 people, according to the NCI.
In Iran, According to a study by Ferdosi et al. (2017), there were more incidence cases of melanoma in males than females accounting for about, 50.63% and 49.37% cases respectively.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Refractory Metastatic Melanoma pipeline therapies. It also thoroughly assesses the Refractory Metastatic Melanoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Refractory Metastatic Melanoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Refractory Metastatic Melanoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Refractory Metastatic Melanoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Refractory Metastatic Melanoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Refractory Metastatic Melanoma Epidemiology, Segmented as –
Incident Cases of Melanoma in the 7MM
First-line Treatable Cases of Melanoma in the 7MM
Stage-specific Cases of Melanoma in the 7MM
Mutation-specific Cases of Melanoma in the 7MM
Type-specific Cases of Melanoma in the 7MM
Age-specific Cases of Melanoma in the 7MM
Relapsed/Refractory Cases of Melanoma in the 7MM
Refractory Metastatic Melanoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Refractory Metastatic Melanoma market or expected to be launched during the study period. The analysis covers the Refractory Metastatic Melanoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Refractory Metastatic Melanoma drugs based on their sale and market share.
The report also covers the Refractory Metastatic Melanoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Refractory Metastatic Melanoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Refractory Metastatic Melanoma Market Will Evolve and Grow by 2032 @
Refractory Metastatic Melanoma Therapeutics Analysis
Unmet needs in refractory metastatic melanoma include limited treatment options, resistance to therapies, predicting treatment response, managing brain metastases, minimizing long-term side effects, ensuring access to advanced therapies, addressing holistic patient needs, researching biomarkers and combination therapies, understanding resistance mechanisms, and empowering patients through education and advocacy. Collaborative efforts and a patient-centered approach are crucial for progress in this challenging condition.
Treatment for refractory metastatic melanoma can be challenging, as these tumors have shown resistance to standard therapies. Historically, conventional treatments for metastatic melanoma included chemotherapy, immunotherapy, targeted therapy, radiation therapy, and surgery. However, recent advances in immunotherapy and targeted therapy have significantly improved outcomes for many patients with advanced melanoma.
Drugs like checkpoint inhibitors (e.g., pembrolizumab, nivolumab) work by blocking certain proteins that prevent immune cells from attacking cancer cells. These drugs have shown remarkable success in treating metastatic melanoma. Some melanomas have specific genetic mutations (e.g., BRAF, NRAS) that can be targeted with specific drugs (e.g., vemurafenib, dabrafenib). These drugs work by inhibiting the activity of these mutated proteins.
Several major pharma and biotech companies are developing therapies for Refractory metastatic melanoma. Currently, Idera Pharmaceuticals is leading the therapeutics market with its Refractory metastatic melanoma drug candidates in the mid to advanced stage of clinical development.
Refractory Metastatic Melanoma Companies Actively Working in the Therapeutics Market Include
And Many Others
Emerging and Marketed Refractory Metastatic Melanoma Therapies Covered in the Report Include:
IMO-2125: Idera Pharmaceuticals
Linrodostat: Bristol-Myers Squibb
Zimberelimab + domvanalimab: Arcus Biosciences
Lerapolturev ± PD-1 inhibitor: Istari Oncology
GEN1042 / BNT312: Genmab / BioNTech
mRNA-2752 ± durvalumab: Moderna
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Refractory Metastatic Melanoma Competitive Intelligence Analysis
4. Refractory Metastatic Melanoma Market Overview at a Glance
5. Refractory Metastatic Melanoma Disease Background and Overview
6. Refractory Metastatic Melanoma Patient Journey
7. Refractory Metastatic Melanoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Refractory Metastatic Melanoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Refractory Metastatic Melanoma Unmet Needs
10. Key Endpoints of Refractory Metastatic Melanoma Treatment
11. Refractory Metastatic Melanoma Marketed Therapies
12. Refractory Metastatic Melanoma Emerging Drugs and Latest Therapeutic Advances
13. Refractory Metastatic Melanoma Seven Major Market Analysis
14. Attribute Analysis
15. Refractory Metastatic Melanoma Market Outlook (In US, EU5, and Japan)
16. Refractory Metastatic Melanoma Companies Active in the Market
17. Refractory Metastatic Melanoma Access and Reimbursement Overview
18. KOL Views on the Refractory Metastatic Melanoma Market
19. Refractory Metastatic Melanoma Market Drivers
20. Refractory Metastatic Melanoma Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Epidermolysis Bullosa market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Epidermolysis Bullosa market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States